Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2023-10-18 Capital/Financing Update
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
BIOS_PR_ GTO15_FR_Final.pdf
Capital/Financing Update Classification · 99% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE – INFORMATION PRIVILEGIÉE" (Press Release – Privileged Information) and is dated 18/10/2023. The content details a specific financial arrangement: securing financing until January 2024 by finalizing the existing convertible bond program with GTO15, including the withdrawal of a conversion notice in exchange for compensation. This is a direct announcement of a significant financing/capital structure event. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER) which focuses on results, or a simple Report Publication Announcement (RPA) as it contains the substantive details of the financing agreement itself.
2023-10-18 French
BIOS_PR_2023-10-16_Transparency Notification_Multiple_EN_Final.pdf
Major Shareholding Notification Classification · 99% confidence The document is a press release dated October 17, 2022, announcing that BioSenic has received transparency notifications from several major shareholders (François Rieger, Véronique Pomi, FA Dièse 3 SAS, and Capital Grand Est SAS). These notifications detail changes in their voting rights percentages, specifically crossing below certain disclosure thresholds (20%, 10%, 5%). This content directly relates to changes in significant share ownership and voting rights disclosure requirements. This aligns perfectly with the definition of 'Major Shareholding Notification' (Code: MRQ). It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K), but a specific regulatory disclosure regarding ownership structure.
2023-10-17 English
BIOS_PR_2023-10-16_Transparency Notification_Multiple_EN_Final_Corrected.pdf
Director's Dealing Classification · 98% confidence The document is a press release dated October 17, 2023, announcing transparency notifications received from several individuals/entities regarding changes in their shareholdings (crossing thresholds like 20%, 10%, and 5%). This content directly relates to changes in significant share ownership levels, which aligns precisely with the definition of Major Shareholding Notification (MRQ). The document details the 'notified details' including the new percentage of voting rights held by each party after a transaction date, confirming it is a notification of a change in major shareholding, not a general regulatory filing (RNS) or a report itself.
2023-10-17 English
BIOS_PR_2023-10-12_Transparency Notification_Multiple_FR_Final.pdf
Major Shareholding Notification Classification · 98% confidence The document is a press release from BioSenic dated October 17, 2023, announcing the receipt of 'notifications de transparence' (transparency notifications) from several major shareholders (François Rieger, Véronique Pomi, FA Dièse 3 SAS, and Capital Grand Est SAS). These notifications detail changes in shareholdings that crossed specific ownership thresholds (20%, 10%, 5%). This content directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. Although it involves insider transactions (directors/major shareholders), the primary focus is the regulatory notification of ownership percentage changes, making MRQ the most precise fit over DIRS (Director's Dealing) or RNS (General Regulatory Filing). The document is an announcement, not a full regulatory form, but the specific nature of the content overrides the general RPA/RNS fallback.
2023-10-17 French
BIOS_PR_2023-October_Denominator_EN_Final.pdf
Major Shareholding Notification Classification · 95% confidence The document is explicitly titled "PRESS RELEASE – REGULATED INFORMATION" and dated 05/10/2023. The content details an announcement regarding the "total number of voting rights and shares" as of September 30, 2023, following the issuance of new shares due to convertible bond conversion. This type of mandatory disclosure, which updates the denominator for potential shareholder dilution and voting power, directly corresponds to a notification about changes in share structure or major shareholdings. While it involves share numbers, it is not a general capital change announcement (SHA) or a transaction in own shares (POS), but rather a specific regulatory disclosure about the total number of voting rights. This fits best under Major Shareholding Notification (MRQ) as it updates the total share count which is crucial for major shareholder calculations, or potentially a general Regulatory Filing (RNS). Given the specific nature of updating the total number of voting rights/shares as required by Belgian law (Article 15), it is a specific disclosure related to ownership structure changes. However, since the core content is the calculation of the total number of shares with voting rights (the denominator), it aligns most closely with the intent of a Major Shareholding Notification (MRQ) or a general regulatory update. Since the document explicitly states the information is published in accordance with the law on the publication of major shareholdings, MRQ is the most precise fit among the specialized codes, although RNS is a strong fallback. I will classify it as MRQ due to the explicit reference to the law governing major shareholdings and the calculation of the total voting rights denominator.
2023-10-05 English
BIOS_PR_2023-octobre_Denominator_FR_Final.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE" (Press Release – Regulated Information) dated 05/10/2023. The core content details an increase in the total number of voting rights and shares due to the conversion of convertible bonds, providing specific figures for capital, shares, and potential future shares from warrants and convertible notes as of August 31, 2023, and September 30, 2023. This type of mandatory disclosure regarding changes in the total number of shares/voting rights (often referred to as the denominator) is a specific regulatory filing requirement, particularly in European markets (indicated by the Belgian law reference). This content directly relates to changes in share capital and voting structure, which aligns best with the 'Share Issue/Capital Change' category (SHA) or potentially a general 'Regulatory Filing' (RNS). Since it specifically details the calculation of the total number of shares/voting rights (the denominator), SHA is the most precise fit, as it covers capital structure changes. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). Given the explicit focus on the total number of shares and voting rights following a capital event (conversion), SHA is the correct classification.
2023-10-05 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.